Overview

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Status:
RECRUITING

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

Phase:

PHASE3

Details

Lead Sponsor:

Daiichi Sankyo

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Docetaxel
Irinotecan
Paclitaxel